Navigation Links
Cardium Reports on Presentation at American Heart Association Meeting Relating to Gene Delivery to the Heart and Generx Clinical Development
Date:11/15/2010

lferminogene tadenovec, Ad5FGF-4) is a DNA-based angiogenic growth factor therapeutic product candidate representing a new class of cardiovascular biologics as a treatment for patients with advanced coronary artery disease.  Generx is designed to stimulate and promote the growth of collateral vessels to enhance myocardial blood flow (perfusion) following a one-time intracoronary administration from a standard cardiac infusion catheter in patients who have insufficient blood flow due to atherosclerotic plaque build-up in the coronary arteries.  Generx has progressed through four randomized, placebo controlled clinical studies at over 100 medical centers in the United States and Western Europe that have enrolled over 650 patients.

In June 2010, Cardium announced that it had entered into a Master Services Agreement with bioRASI, an international contract research organization, to assist in the conduct of a late-stage clinical study (ASPIRE) designed to support regulatory approval and commercialization activities for Generx in Russia and affiliated jurisdictions, as well as in other newly industrializing markets.  The Generx clinical study will be conducted at three leading medical centers in Moscow and will be a randomized, controlled, parallel-group, multi-center study to evaluate the safety and efficacy of Generx using SPECT imaging of myocardial blood flow in patients with stable angina pectoris.  The primary endpoint will be the change in reversible perfusion defect size as measured by SPECT imaging, which is directly analogous to that successfully used in a Phase 2a clinical study of Generx in the United States.  

Positive results from the prior Phase 2a clinical study (Grines et al., J Am Coll Cardiol 2003; 42:1339-47) showed that Generx improved myocardial blood flow in the ischemic region of the hearts of men and women following a single intracoronary infusion as measured by the objective efficacy endpoint o
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Aware, Inc. Reports Third Quarter 2010 Financial Results
2. Smithsonian reports regional sea temperature rise and coral bleaching event in Western Caribbean
3. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
4. Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
5. GEN reports on the greening of the life sciences
6. Aware, Inc. Reports Second Quarter 2010 Financial Results
7. GEN reports on rediscovered technology to bolster proteomics research
8. BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results
9. International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit
10. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
11. New climate change reports underscore need for action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... stressed they are often grouchy, grumpy, nasty, distracted or ... EPFL have just highlighted a fundamental synaptic mechanism that ... of social skills and cognitive impairment. When triggered by ... the brain. This was revealed by a work published ... team went to look for answers in a region ...
(Date:9/18/2014)... in the protective tentacles of host anemones, but new ... of kilometres across the open ocean. Although the process ... this is the first time that the high level ... , Dr Steve Simpson, Senior Lecturer in Marine Biology ... colleagues from the Australian Research Council Centre of Excellence ...
(Date:9/17/2014)... doctoral student have designed a device based on a ... and dew., The device could provide water in drought-stricken ... Cheng Luo, professor in the Mechanical & Aerospace Engineering ... College of Engineering department, published "Bioinspired Plate-Based Fog Collectors" ... Society) Applied Materials & Interfaces ...
Breaking Biology News(10 mins):How stress tears us apart 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Shorebird's beak inspires UT Arlington research on water collection 2
... mothers than duller birds, according to a new study led ... see ultra-violet (UV) light. While the crown of a blue ... has the added dimension of appearing UV-reflectant. , The three-year ... University of California Davis, USA and the University of Glasgow, ...
... Dartmouth researchers has uncovered a protein that plays a vital ... key step in improving the production and quality of crops ... journal PNAS . The team included researchers ... Lausanne. Plant roots use their endodermis, or inner skin, ...
... stem cells and DNA-cutting protein from meningitis bacteria, researchers ... have created an efficient way to target and repair ... Aug. 12, 2013) in the Proceedings of the ... the novel technique is much simpler than previous methods ...
Cached Biology News:Bright birds make good mothers 2New gene repair technique promises advances in regenerative medicine 2
(Date:9/18/2014)... Research and Markets has announced the addition ... Report, 2014-2017" report to their offering. ... differentiate into specialized cells and can divide (through mitosis) ... be applied to treatment of cardiovascular diseases, leukemia (a ... or lesion of liver, kidney and other parenchymal organs, ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... a FM-4910 listed material, to stay competitive in ... These high-performance materials ultimately impact product quality ... President and owner. , Established in 1980 in ... strong as many fabricators have left the business. ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
(Date:9/18/2014)... SeqLL Inc., the owner of the ... the closing of a $1M Series-A funding round. ... Technologies, will increase the power of tSMS™ technology ... March 2013 by Daniel Jones, a former Field ... SeqLL has continued to offer Helicos’ sequencing technology, ...
Breaking Biology Technology:Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
... MONTREAL , Feb. 1 /PRNewswire-FirstCall/ - ICBS Ltd. (OTCPK: ... TOGS(TM) 3000 bio-photonic incubation & detection systems, which the company will ... 100% accuracy in the detection of Total Coli forms and E. ... to introduce the new TOGS(TM) 3000 in the U.S, and overseas." ...
... The ... as a regulatory consultant after retiring from Eli Lilly & Co. Dr. ... human pharmaceutical products, including director of regulatory affairs and clinical research. Dr. ... submissions. , ...
... Data Demonstrating a 35% Overall Response Rate with a ... Relapsed or Relapsed/Refractory Waldenstrom,s Macroglobulinemia to be Published in ... Journal of Clinical Cancer Research , QUÉBEC CITY, ... AEZS ; TSX: AEZ) (the "Company"), a late-stage ...
Cached Biology Technology:BioSpec Global Solutions Inc, takes delivery of new TOG's 3000 Home edition for the U.S. and international markets 2Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 3Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 4Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 5
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
Printer paper for Model 680 series readers is used with the thermal printers of the Model 680 and Model 680 XR microplate readers. Supplied as 2 rolls....
... with the drug discovery process in mind. ... performance, Safire is the ideal instrument to ... high throughput screening. Safire is a fully ... a range of high speed detection techniques. ...
... cocktail is tailored to efficiently ... suspensions of non-human primate (Rhesus ... using the StemSep (or compatible ... system, achieving a 2.6 Log ...
Biology Products: